RCS - N4 Pharma PLC - Investor Presentation

N4 PharmaAnnouncement

02/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB2596Oa&default-theme=true

RNS Number : 2596O  N4 Pharma PLC  02 October 2023

Reach - Non-Regulatory

 

2 October 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Investor Presentation

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce that an updated investor presentation ("Presentation")
incorporating the Company's acquisition of a 71% interest in Nanogencis
Limited is now available on the N4 Pharma website.  To view a copy of the
Presentation, please click
here: http://www.rns-pdf.londonstockexchange.com/rns/2596O_1-2023-10-1.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2596O_1-2023-10-1.pdf)

 

 

Enquiries:

 N4 Pharma Plc                                          Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                         Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                  Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                   Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre-clinical and
clinical programs, N4 Pharma will seek to receive upfront payments, milestone
payments and ultimately royalty payments once products reach the market.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFSDITLLIIV